Lifesci Capital Predicts Neurogene FY2025 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Neurogene in a report issued on Monday, January 26th. Lifesci Capital analyst P. Dolezal expects that the company will post earnings per share of ($4.26) for the year. Lifesci Capital currently has a “Outperform” rating and a $50.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Lifesci Capital also issued estimates for Neurogene’s Q4 2025 earnings at ($1.17) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.33) EPS, FY2027 earnings at ($3.96) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at $5.80 EPS and FY2030 earnings at $12.83 EPS.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.27.

Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Neurogene in a report on Tuesday, January 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Stock Performance

Neurogene stock opened at $18.89 on Wednesday. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $37.27. The firm has a market capitalization of $292.61 million, a price-to-earnings ratio of -4.60 and a beta of 1.60. The stock’s fifty day moving average is $19.62 and its two-hundred day moving average is $21.97.

Institutional Trading of Neurogene

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC lifted its stake in shares of Neurogene by 55.0% during the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after purchasing an additional 59,479 shares during the period. Schroder Investment Management Group purchased a new stake in shares of Neurogene in the second quarter valued at $451,000. PNC Financial Services Group Inc. increased its stake in Neurogene by 43.6% in the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after purchasing an additional 1,232 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its position in Neurogene by 1.8% during the third quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after buying an additional 10,442 shares during the period. Finally, ADAR1 Capital Management LLC lifted its position in Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after buying an additional 1,008 shares during the period. 52.37% of the stock is owned by hedge funds and other institutional investors.

More Neurogene News

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: Lifesci Capital initiated coverage with an “Outperform” rating and a $50 price target, creating a clear upside thesis and a potential catalyst for buying interest. Lifesci Capital Begins Coverage on Neurogene
• Positive Sentiment: The analyst model projects a major earnings turnaround long term (FY2029 EPS $5.80; FY2030 EPS $12.83), signaling expectations for successful late‑stage commercialization or substantial revenue growth several years out.
• Neutral Sentiment: Lifesci provided a full schedule of quarterly and annual forecasts (Q1–Q4 2026 and FY2025–FY2030), giving investors a detailed roadmap to test management execution vs. the model over time.
• Negative Sentiment: Near‑term estimates are for continued sizable losses: FY2025 ~($4.26), FY2026 ~($4.33) and FY2027 ~($3.96), with quarterly 2026 EPS forecasts near (‑$1.2). That implies ongoing cash burn and dilution risk until revenue inflection.
• Negative Sentiment: Technicals and liquidity may be weighing on the stock: shares are trading below the 50‑day ($19.65) and 200‑day ($21.99) SMAs, market cap is modest, and recent volume is below average — factors that can amplify downward moves while the company remains unprofitable.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.